Format

Send to

Choose Destination
Clin Lab Med. 2014 Mar;34(1):43-58, vi. doi: 10.1016/j.cll.2013.11.007. Epub 2014 Jan 14.

Natriuretic peptides in heart failure and acute coronary syndrome.

Author information

1
Cardiology Division, Massachusetts General Hospital, Yawkey 5B, 55 Fruit Street, Boston, MA 02114, USA.
2
Cardiology Division, Massachusetts General Hospital, Yawkey 5B, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: jjanuzzi@partners.org.

Abstract

B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are the gold standard biomarkers in determining heart failure (HF) diagnosis and prognosis. These natriuretic peptides may also be useful in guiding HF management, but further studies are needed before they can be routinely recommended for that purpose. A novel natriuretic peptide biomarker, mid-regional pro atrial natriuretic peptide (MR-proANP), shows promise in determining diagnosis and prognosis in HF patients. BNP and NT-proBNP may be of use in excluding myocardial infarction and to assist in determining prognosis in acute coronary syndrome (ACS). Therapeutic implication of natriuretic peptides in ACS is unclear.

KEYWORDS:

Acute coronary syndrome; BNP; Biomarkers; Cardiac markers; Heart failure; Laboratory medicine; NT-proBNP; Natriuretic peptides

PMID:
24507786
DOI:
10.1016/j.cll.2013.11.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center